Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Boehringer discontinues brigimadlin while others continue to struggle.
The THIO-104 study listing is live, along with questions about funding the trial.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.